BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/16/2015 2:22:00 PM | Browse: 986 | Download: 1246
Publication Name World Journal of Hepatology
Manuscript ID 16314
Country/Territory Japan
Received
2015-01-10 13:46
Peer-Review Started
2015-01-10 14:27
To Make the First Decision
2015-03-06 10:32
Return for Revision
2015-03-11 11:33
Revised
2015-03-16 12:32
Second Decision
2015-04-20 11:41
Accepted by Journal Editor-in-Chief
2015-04-20 17:22
Accepted by Company Editor-in-Chief
2015-04-30 11:31
Articles in Press
2015-04-30 11:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2015-05-29 15:48
Publish the Manuscript Online
2015-06-16 14:22
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Current and future directions for treating hepatitis B virus infection
Manuscript Source Invited Manuscript
All Author List Akinobu Tawada, Tatsuo Kanda and Osamu Yokosuka
Funding Agency and Grant Number
Corresponding Author Tatsuo Kanda, MD, PhD, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8677, Japan. kandat-cib@umin.ac.jp
Key Words Hepatocellular carcinoma; Peginterferon; Nucleotide analogue; Chronic hepatitis B
Core Tip Chronic hepatitis B virus (HBV) infection is one of the major causes of hepatocellular carcinoma, which is a cancer with poor prognosis. We reviewed the natural course of HBV infection and current standard therapies for chronic HBV infection. Peginterferon and nucleos(t)ide analogues, such as entecavir and tenofovir disoproxil fumarate, have several drug-specific advantages and disadvantages. It is difficult to eliminate covalently closed circular DNA of HBV with these current standard therapies. Further improvements of the therapeutic options for HBV infections should be needed.
Publish Date 2015-06-16 14:22
Citation Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552
URL http://www.wjgnet.com/1948-5182/full/v7/i11/1541.htm
DOI http://dx.doi.org/10.4254/wjh.v7.i11.1541
Full Article (PDF) WJH-7-1541.pdf
Full Article (Word) WJH-7-1541.doc
Manuscript File 16314-Review.doc
Answering Reviewers 16314-Answering reviewers.pdf
Audio Core Tip 16314-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 16314-Conflict-of-interest statement.pdf
Copyright License Agreement 16314-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 16314-Language certificate.pdf
Peer-review Report 16314-Peer-review(s).pdf
Journal Editor-in-Chief Review Report 16314-Journal editor-in-chief review report.pdf
Scientific Misconduct Check 16314-Scientific misconduct check.pdf
Scientific Editor Work List 16314-Scientific editor work list.pdf